Pre-clinical activity of taxol in non-seminomatous germ cell tumor cell lines and nude mouse xenografts

Investigational New Drugs

Volumn 15, Issue 2, 1997, Pages 91-98

  Dunn, T A ^a   Grunwald V ^a   Bokemeyer, C ^b   Casper, J ^c   Schmoll, H J ^d  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c UNIVERSITY OF ROSTOCK   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

Cytotoxic drugs; Drug resistance; Human germ cell cancer; Taxol

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IFOSFAMIDE; PACLITAXEL;

ANIMAL EXPERIMENT; ARTICLE; CROSS RESISTANCE; DRUG CYTOTOXICITY; DRUG RESISTANCE; EXPERIMENTAL NEOPLASM; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE; TUMOR XENOGRAFT;

ANIMALS; CISPLATIN; GERMINOMA; HUMANS; IFOSFAMIDE; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PACLITAXEL; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR STEM CELLS;

EID: 0030994436     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005852521656     Document Type: Article

References (38)

1. Einhorn LH: Testicular cancer: A model for a curable neoplasm: Cancer Res 41:3275-3280, 1981
2. Siegert W, Beyer J, Strohscheer I, Baurmann H, Oettle H, Zingsern J, Zimmerman R, Bokemeyer C, Schmoll HJ, Huhn D: High dose treatment with carboplatin, etoposide and ifosfamide followed by autologous stem cell transplantation in relapsed or refractory germ cell tumors - a phase I/II study. The German Testicular Cancer Cooperative Study Group. J Clin Oncol 12:1223-1231, 1994
3. Bokemeyer C, Droz JP, Hanauske A, Schmoll HJ: Treatment of relapsed germ cell tumors with vinorelbine: A trial of the phase I/II study group of the association for medical oncology of the German cancer society. Onkologie 16:29-31, 1993
4. Harstrick A, Schmoll HJ, Wilke H, Schober C, Stahl M, Wimpner CK, Bokemeyer C, Dolken G, Burk K, Poliwoda H: High-dose epirubicin in refractory or relapsed nonseminomatous testicular cancer: A phase II study. Ann Oncol 1(5):375-376, 1990
5. Bokemeyer C, Schmoll HJ, Natt F, Knoche M, Beyer J, Souchon R: Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer: J Cancer Res Clin Oncol 120:754-757,1994
6. Schiff PB, Fant J, Horwitz SB: Promotion of microtubule assembly in vitro by taxol. Nature 277:655-667, 1979
7. Santibanez JF, Maccioni RB, Martinez J: The secretion of urokinase-like plasminogen activator is inhibited by microtubule-interacting drugs. Cell-Biochem-Funct., 13(3):217-225, 1995
8. Verschueren H, Dewit J, De Braekeleer J, Schirrmacher V, De Baetselier P: Motility and invasive potency of murine Tlymphoma cells: effect of microtubule inhibitors. Cell Biol Int 18(1):11-19, 1994
9. Kohn EC, Sarosy G, Bicher A et al.: dose intense taxol: High response rate in patients with platinum-resistant recurrent ovarian cancer. J Natl Cancer Inst 86:180-224, 1994
10. McGuire WP, Rowinsky EK, Rosenhein NB: Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med 111:273-279, 1989
11. Motzer RJ, Chou TC, Schwartz L, Bosl GJ, Bajorin DF, Hutter H: Paclitaxel in germ cell cancer. Semin Oncol 22(3 Suppl 6):12-15, 1995
12. Reichman BS, Seidman AD, Crown JP et al.: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 83:1797-1805, 1993
13. Bokemeyer C, Beyer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ: Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory cancer. Annals Oncol 7:31-34, 1996
14. Georgiadis MS, Schuler B, Johnson BE: Four-day paclitaxel infusion with cisplatin for patients with lung cancer. Semin Oncol 4 (Suppl 9):67-69, 1995
15. Hill BT, Whelan RD, Shellard SA, McClean S, Hosking LK: Differential cytotoxic effects of docetaxel in a range of mammalian tumor cell lines and certain drug-resistant sublines in vitro. Invest New Drugs 12(3):169-182, 1994
16. Hill BT, Shellard SA, Fichtinger-Schepman A, Schmoll HJ, Harstrick A: Differential formation and enhanced removal of specific cisplatin-DNA adducts in two cisplatin-selected resistant human testicular teratoma sublines: Anti-Cancer Drugs 5(3):321-328, 1994
17. Casper J, Schmoll HJ, Schnaidt U, Fonatsch C: Cell lines of human germinal cancer. Int J Androl 10:105-113, 1987
18. Harstrick A, Casper J, Schmoll HJ: Comparative antitumor activity of cisplatin and two new cisplatin-analogues JM8 and JM9 in human testicular xenografts: Int J Androl 10(1): 139-145, 1987
19. Harstrick A, Bokemeyer C, Scharnofkse M, Hapke G, Reile D, Schmoll HJ: Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, gastric carcinoma cell lines. Cancer Chemother Pharmacol 33:43-47, 1993
20. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Schmoll HJ: Comparison of the antitumor activity of cisplatin, carboplatin, and iproplatin against established human testicular cancer cell lines in vivo and in vitro. Cancer 63:1079-1083, 1989
21. Harstrick A, Casper J, Guba R, Wilke H, Poliwoda H, Leanz L, Schmoll HJ: Testicular cancer cell lines heterotransplanted in nude mice as a preclinical test system for new anticancer agents. Proc Am Assoc Cancer Res 30:2461, 1989
22. Berdel WE, Berger MR, Falk H, Harstrick A, Danhauser S, Schick HD: Lack of therapeutic activity of the lipoidal amine CP-46.665 in rodent tumors and human non-seminomatous germ cell tumors growing in nude mice. Cancer Lett 38:191-197, 1987
23. Harstrick A, Casper J, Pieper A, Guba R, Reile D, Schumacher S, Schnaidt U: Activity of antineoplastic agents in human testicular tumor bearing nude mice. Blut 51:178, 1985
24. Harstrick A, Casper J, Kohne-Wompner H, Wilke H, Schmoll HJ, Poliwoda H: Comparative activity of 4 antracyclines against heterotransplanted germ cell tumor cell lines. Invest New Drugs 8 Suppl 1:S19-S24, 1990
25. Wang N, Trend B, Bronson DL, Fraley EE: Nonrandom abnormalities in chromosome 1 in human testicular cancers. Cancer Res 40:796-802, 1980
26. Bronson DL, Andrews PW, Vassella RL, Fraley EE: In vitro differentiation of human embryonal carcinoma cells. In: Teratocarcinoma Stem Cells, Silver LM, Martin GR, Strickland S (eds). 10th Edition: 597-605, 1983
27. Vogelzang NJ, Bronson DL, Savino D, Vassella R, Fraley EF: A human embryonal-yolk sac carcinoma model system in athymic nude mice. Cancer 55(11):2584-2593, 1985
28. Skehan P, Storeng R, Scudiero D, Monks A, McMahan J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colorimetric cytotoxicity assay for anticancer drug screening. J Natl Cancer Inst 82:1107-1112 ,1990
29. Dunn T, Schmoll HJ, Grunwald V, Bokemeyer C: Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell cancer cell lines. Paper submitted.
30. Nygren P, Csoka K, Jonsson B, Fridborg H, Bergh J, Hagberg H, Glimelius B, Brodin O, Tholander B, Kreuger A: The cytotoxic activity of Taxol in primary cultures of tumour cells from patients is partly mediated by Cremophor EL. Br J Cancer 71(3):478-481, 1995
31. Freireich EJ, Gehan EA, Rail DP, Schmidt LH, Skipper HE: Quantitative comparison of toxicity of anti-cancer agents in mouse, rat, horse, dog, monkey and man. Cancer Chemotherapy Reports 50:219-244, 1966
32. Donaldson KL, Goolsby GL, Kiener PA, Wahl AF: Activation of p34cdc2 coincident with taxol-induced apoptosis. Cell Growth Differ 5(10):1041-1050, 1994
33. Bedford P, Fichtinger-Schepman AMJ, Shellard S, Walker MC, Masters JRW, Hill BT: Differential repair of platinum-DNA adducts in human bladder and testicular tumor continuous cell lines. Cancer Res 48:3019-3024, 1988
34. Pera MF, Friedlos F, Mills J, Roberts JJ: Inherent sensitivity of cultured human embryonal carcinoma cells to adducts of cisdiamminedichloroplatinum (II) on DNA: Cancer Res 47:6810-6813, 1987
35. Andrews PW, Banting G, Damjanov I, Arnaud D, Avner P: Three monoclonal antibodies defining distinct differentiation antigens associated with different high molecular weight polypeptides on the surface of human embryonal carcinoma cells. Hybridoma 3:347-361, 1984
36. Pera MF, Blasco-Lafita MJ, Cooper S, Mason M, Mills J, Monoghan P: Analysis of cell-differentiation lineage in human teratomas using new monoclonal antibodies to cytostructural antigens of embryonal carcinoma cells. Differentiation 39:139-149, 1988
37. Reed E, Patrker RJ, Dabholkar M: Taxol effect on cisplatin-DNA adduct repair in human ovarian cancer cells. Second National Cancer Institute Workshop on Taxol, Alexandria, VA (Abst) 1992
38. Reed E, Kohn EC, Sarosy G, Dabholkar M, Davis P, Jacob J, Maher M: Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results. Semin Oncol 3 (Suppl 6):90-96, 1995